AHIMA, ECRI partnering on patient safety pilot

The American Health Information Management Association (AHIMA) and the ECRI Institute are partnering in a pilot project to promote patient safety and quality care through the reduction of health IT risks, and enhancing health IT innovation.

The Partnership for Promoting Health IT Patient Safety will create a national framework to proactively identify and resolve health IT safety issues based on various health IT events and hazards, according to a release. 

AHIMA will join ECRI Institute’s partners including providers, health IT vendors, public policy organizations and other professional organizations to collect and analyze health data and report results to improve patient safety within health IT. AHIMA will support the adaptation and dissemination of lessons learned to its members and other stakeholders.

“Patient safety has always been a top priority for AHIMA and our members,” said AHIMA CEO Lynne Thomas Gordon, MBA, RHIA. “AHIMA’s participation in this vital project will help identify current and future patient safety risks. We can then work together to develop strategies to remedy these problems and ideally prevent them from occurring again.”

AHIMA and ECRI are planning to develop resources on health IT hazards including webinars for AHIMA’s members and a special panel discussion during AHIMA’s Annual Convention and Exhibit in San Diego in October.

“We know a lot about usability issues when it comes to health IT. This new effort, though, will look at how to implement technology, how to structure leadership and how to avoid health IT safety risks,” said ECRI Executive Vice President and General Counsel Ronni Solomon.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.